共 6 条
[1]
Therapeutic effects of a novel tylophorine analog; NK‐007; on collagen‐induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation[J] Ti Wen;Yangguang Li;Meng Wu;Xiaolin Sun;Xiucong Bao;Yuquan Lin;Jianlei Hao;Lin Han;Guangchao Cao;Ziwen Wang;Yuxiu Liu;Zhenzhou Wu;Zhangyong Hong;Puyue Wang;Liqing Zhao;Zhanguo Li;Qingmin Wang;Zhinan Yin Arthritis & Rheumatism 2012,
[2]
Phase II study of tofacitinib (CP‐690;550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate[J] Yoshiya Tanaka;Makoto Suzuki;Hiroyuki Nakamura;Shigeyuki Toyoizumi;Samuel H. Zwillich; Arthritis Care Res 2011,
[3]
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab; etanercept; and infliximab using patient level data[J] JohanAskling;KyleFahrbach;BethNordstrom;SusanRoss;Christopher H.Schmid;DeborahSymmons Pharmacoepidem. Drug Safe. 2011,
[4]
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy[J] Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai;Tsutomu Takeuchi;Junichi Azuma;Tadamitsu Kishimoto Modern Rheumatology 2009,
[5]
Long-term safety study of iguratimod in patients with rheumatoid arthritis[J] Masako Hara;Tohru Abe;Sachiko Sugawara;Yutaka Mizushima;Keiko Hoshi;Shoichiro Irimajiri;Hiroshi Hashimoto;Shinichi Yoshino;Nobuo Matsui;Masashi Nobunaga Modern Rheumatology 2007,
[6]
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled; multicenter; double-blind; parallel-group study[J] Masako Hara;Tohru Abe;Sachiko Sugawara;Yutaka Mizushima;Keiko Hoshi;Shoichiro Irimajiri;Hiroshi Hashimoto;Shinichi Yoshino;Nobuo Matsui;Masashi Nobunaga;Shigeyuki Nakano Modern Rheumatology 2007,